Sinco Pharmaceuticals Holdings Limited
HKEX:6833.HK
0.184 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,540.063 | 2,271.505 | 2,024.055 | 2,049.803 | 1,176.409 | 952.957 | 806.723 | 858.894 | 1,096.071 | 950.079 | 532.48 |
| Cost of Revenue
| 2,216.783 | 1,965.637 | 1,659.105 | 1,775.977 | 956.562 | 849.807 | 738.403 | 754.326 | 943.564 | 820.309 | 471.361 |
| Gross Profit
| 323.28 | 305.868 | 364.95 | 273.826 | 219.847 | 103.15 | 68.32 | 104.568 | 152.507 | 129.77 | 61.119 |
| Gross Profit Ratio
| 0.127 | 0.135 | 0.18 | 0.134 | 0.187 | 0.108 | 0.085 | 0.122 | 0.139 | 0.137 | 0.115 |
| Reseach & Development Expenses
| 8.291 | 11.27 | 26.16 | 0.812 | 1.585 | 2.074 | 1.996 | 5.089 | 3.028 | 1.725 | 0.77 |
| General & Administrative Expenses
| 108.862 | 80.585 | 65.001 | 40.119 | 45.178 | 55.497 | 57.256 | 62.419 | 40.524 | 17.52 | 9.866 |
| Selling & Marketing Expenses
| 93.713 | 117.016 | 105.375 | 89.836 | 114.536 | 268.576 | 95.919 | 11.47 | 5.709 | 6.792 | 2.358 |
| SG&A
| 202.575 | 204.644 | 172.396 | 130.038 | 161.667 | 325.024 | 153.175 | 73.889 | 46.233 | 24.312 | 12.224 |
| Other Expenses
| -6.467 | 0.311 | 1.368 | -3.818 | -6.174 | -121.03 | -39.223 | -4.459 | -13.358 | -7.715 | 0 |
| Operating Expenses
| 205.501 | 195.185 | 177.431 | 132.955 | 157.177 | 340.974 | 232.666 | 72.28 | 59.154 | 31.134 | 9.474 |
| Operating Income
| 116.46 | 101.224 | 192.554 | 143.788 | 58.18 | -217.011 | -84.855 | 30.679 | 106.274 | 105.458 | 48.895 |
| Operating Income Ratio
| 0.046 | 0.045 | 0.095 | 0.07 | 0.049 | -0.228 | -0.105 | 0.036 | 0.097 | 0.111 | 0.092 |
| Total Other Income Expenses Net
| -16.579 | -1.932 | -25.167 | -7.833 | -15.225 | -55.004 | -110.013 | -5.113 | -19.636 | -11.646 | 2.024 |
| Income Before Tax
| 99.881 | 99.292 | 167.387 | 135.955 | 42.955 | -272.015 | -194.868 | 25.566 | 86.638 | 93.812 | 50.919 |
| Income Before Tax Ratio
| 0.039 | 0.044 | 0.083 | 0.066 | 0.037 | -0.285 | -0.242 | 0.03 | 0.079 | 0.099 | 0.096 |
| Income Tax Expense
| 57.529 | 29.83 | 32.304 | 17.818 | 19.405 | 8.6 | 8.971 | 7.229 | 17.197 | 13.683 | 7.932 |
| Net Income
| 42.352 | 69.462 | 135.083 | 118.137 | 22.898 | -280.614 | -185.896 | 19.367 | 69.614 | 69.367 | 36.539 |
| Net Income Ratio
| 0.017 | 0.031 | 0.067 | 0.058 | 0.019 | -0.294 | -0.23 | 0.023 | 0.064 | 0.073 | 0.069 |
| EPS
| 0.021 | 0.034 | 0.078 | 0.07 | 0.014 | -0.17 | -0.12 | 0.013 | 0.058 | 0.058 | 0.03 |
| EPS Diluted
| 0.021 | 0.034 | 0.078 | 0.07 | 0.014 | -0.17 | -0.12 | 0.013 | 0.058 | 0.058 | 0.03 |
| EBITDA
| 128.972 | 109.011 | 197.691 | 152.046 | 67.507 | -206.648 | -69.606 | 41.277 | 116.503 | 107.336 | 49.901 |
| EBITDA Ratio
| 0.051 | 0.048 | 0.098 | 0.074 | 0.057 | -0.217 | -0.086 | 0.048 | 0.106 | 0.113 | 0.094 |